Dr Chris Goddard
Chairman
Pharmaceuticals
AbRegen
Australia
Biography
Dr Chris Goddard is the Chairman of AbRegen. In addition, he is Chief Executive Officer and Managing Director of GroPep Bioreagents, an Adelaide based biotechnology company specialising in the development and manufacture of insulin-like growth factors (IGFs), IGF analogues, IGF binding proteins, polyclonal and monoclonal antibodies. Previous appointments include positions at the University of Sheffield, St. Bartholomew’s Hospital, University of London, Manchester University and the Roslin Institutue. After moving to Australia in 1994, Dr Goddard joined the start up company GroPep Pty Ltd where he built the Cell Culture business that underpinned the company’s financial success. As a member of the senior management team he was involved in the IPO of GroPep in August 2000, became an Executive Director in 2001, acting Chief Executive in 2002 and subsequently the Chief Operating Officer until the acquisition of the company by Novozymes A/S in December 2006 for ~AUD$100 million. He then moved to Novozymes’ corporate headquarters in Copenhagen to a role as Senior Director, Business Development & Acquisitions before returning to Adelaide in 2010 to re-establish GroPep Bioreagents through a management buyout.
Research Interest
Research interest on BIotechnology
